ODI Pharma AB (ODI) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK Million (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.48

Return on Equity

-603.65%

Price to Book

0.00

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Mar 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

13.48%

6 Months

-20.79%

1 Year

-44.06%

2 Years

-65.15%

3 Years

-59.52%

4 Years

-67.22%

5 Years

-69.75%

ODI Pharma AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

42.12%

EBIT Growth (5y)

-9.73%

EBIT to Interest (avg)

-4.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.00

Sales to Capital Employed (avg)

7.29

Tax Ratio

1.78%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.28

EV to EBITDA

0.28

EV to Capital Employed

1.48

EV to Sales

-0.48

PEG Ratio

Dividend Yield

ROCE (Latest)

524.73%

ROE (Latest)

-603.65%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 88.46% vs -73.33% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.10",
          "val2": "-2.30",
          "chgp": "104.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-2.60",
          "chgp": "88.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "28.00%",
          "val2": "0.00%",
          "chgp": "2.80%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 22,200.00% vs -66.67% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 91.30% vs 4.17% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22.30",
          "val2": "0.10",
          "chgp": "22,200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-6.80",
          "chgp": "72.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.60",
          "val2": "-6.90",
          "chgp": "91.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-86.30%",
          "val2": "-48,851.90%",
          "chgp": "4,876.56%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

2.90

0.00

Operating Profit (PBDIT) excl Other Income

0.10

-2.30

104.35%

Interest

0.10

0.30

-66.67%

Exceptional Items

0.00

Consolidate Net Profit

-0.30

-2.60

88.46%

Operating Profit Margin (Excl OI)

28.00%

0.00%

2.80%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 88.46% vs -73.33% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

22.30

0.10

22,200.00%

Operating Profit (PBDIT) excl Other Income

-1.90

-6.80

72.06%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.60

-6.90

91.30%

Operating Profit Margin (Excl OI)

-86.30%

-48,851.90%

4,876.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 22,200.00% vs -66.67% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 91.30% vs 4.17% in Jun 2023

All Annual Results

Company CV

About ODI Pharma AB

ODI Pharma AB

Pharmaceuticals & Biotechnology

Odi Pharma AB (publ) is a Swedish-based pharmaceutical company. The Company is a manufacturer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. The Company is located in Stockholm.

Company Coordinates

Company Details

Engelbrektsgatan 9-11 , STOCKHOLM None : 114 32

Tel:

https://www.odipharma.com/

Registrar Details